Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Serono Extends CNS Collaboration With Newron, Invests In Israel

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck Serono's revised deal with Newron gives the latter a license to develop two additional compounds, with Merck holding a buy-back option.
Advertisement

Related Content

Corporate Venture Eyes The Early Stage
Merck KGaA Pins Cladribine Hopes On Ongoing Studies After Complete Response Letter
Lilly Adds Dual-Acting Insomnia Compound With Acquisition Of Hypnion
Serono Adds Newron Parkinson's Disease Agent Safinamide With Licensing Deal
Serono Adds Newron Parkinson's Disease Agent Safinamide With Licensing Deal
Merck KGaA Drops Parkinson’s Treatment Sarizotan

Topics

Advertisement
UsernamePublicRestriction

Register

PS072041

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel